Abstract:To assess T cell subsets and levels of chemokines and cytokines in patients with SLE and determine their relationships between disease activity and organ involvement. Blood samples from SLE patients (n = 24) and healthy controls (n = 36) were analyzed. Frequency of circulating follicular help T cells (Tfh), central memory T cells (Tcm), effector memory T cells (Tem), and naïve T cell subsets was enumerated and their surface markers expression of inducible T cell co-stimulator (ICOS) and programmed death 1(PD-1) protein was examined by flow cytometry. The disease state in SLE patients was evaluated using the SLE Disease Activity Index (SLEDAI). Concentrations of autoantibodies, serum C-reactive protein (CRP), the erythrocyte sedimentation rate (ESR), lgG, complement 3, complement 4, cytokines, and chemokines, such as IL-21, IL-17A, and IL-1β, were measured. The frequencies of circulating Tfh and Tcm cell subsets were significantly lower than those in healthy controls. However, the percentages of circulating PD1+ICOS+Tfh, PD1+ICOS+Tcm, and PD1+ICOS+Tem of PBMCs from SLE patients were higher than those in healthy controls. Furthermore, increased levels of serum IL-1β, IL-4, IL-6, MCP-1, IL-21, and IL-17A were detected in the patients with SLE compared to healthy controls. In addition, patients with immune thrombocytopenia displayed elevated proportions of serum IL-10, IL-17A, and IL-1β. Aberrant T cell subsets and cytokines expression profile were observed in SLE patients. PD1+ICOS+Tem cell subset was clearly influenced by disease activity and serum IL-10, IL-17A, and IL-1β were significantly increased in patients with immune thrombocytopenia. Therefore, PD1+ICOS+Tem cells might serve as an important tool for recognition and serum IL-10, IL-17A, and IL-1β might be an effective monitor for SLE patients with immune thrombocytopenia.

T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain as a promising immune checkpoint target for the treatment of SLE

TIGIT-Fc fusion protein alleviates murine lupus nephritis through the regulation of SPI-B-PAX5-XBP1 axis-mediated B-cell differentiation

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.

Post-translational Modifications in T Cells in Systemic Erythematosus Lupus

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases

TIGIT signaling pathway negatively regulates CD4+ T cell responses in systemic lupus erythematosus

The expression of TIGIT on peripheral CD4 + T cells from patients with systemic lupus erythematosus and its significance

Elevated Expression of TIGIT on CD3+CD4+ T Cells Correlates with Disease Activity in Systemic Lupus Erythematosus.

TIGIT axis: novel immune checkpoints in anti-leukemia immunity

Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases

Tumor Immune Checkpoints and Their Associated Inhibitors

The Landscape of TIGIT Target and Clinical Application in Diseases

TIGIT as an emerging immune checkpoint

T-cell Immunoglobulin and ITIM Domain in Cancer Immunotherapy: A Focus on Tumor-Infiltrating Regulatory T Cells.

T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer

TIGIT reverses IFN-α-promoted Th1-like Tregs via in-sequence effects dependent on STAT4

TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy

V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy